Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Elemental Analyser

By Drug Discovery Trends Editor | July 15, 2010

exeterWith its wide linear range, combined static and dynamic combustion technology and horizontal furnace design allowing for removal of residues between runs, the Exeter Analytical CE-440 CHN/O/S elemental analyzer is uniquely capable of accurately analyzing the widest range of sample types – quickly, easily and reliably.

Whether you are analyzing organic compounds, pharmaceuticals, petrochemicals, polymers, refractory, environmental or natural materials (soil, plants or insects), determining the percentage Carbon, Hydrogen, Nitrogen, Oxygen and Sulphur in your sample is a basic and essential need.

Employing the combined combustion technique makes it possible for the CE-440 to analyse any sample type, from volatiles to difficult to combust materials including nitrides, graphite fibers, ceramics and even carbides with melting points of over 2000°C.

Offering unmatched operating accuracy and precision the fully automated CE440 delivers simultaneous CHN analysis in less than 5 minutes and Oxygen and Sulphur in only 6 minutes – increasing the productivity of your laboratory.
 
Low gas and reagent consumption combined with high reduction tube life allows the CE440 to deliver some of the lowest operating costs of any CHN/O/S elemental analyzer available. Intuitive Windows based operating software reduces human errors through incorporation of extensive automation, comprehensive customer help and diagnostic facilities.  Most parts on the CE440 are user replaceable further reducing operating costs and downtime.

Exeter Analytical


Filed Under: Drug Discovery

 

Related Articles Read More >

Bayer’s Lynkuet approved by FDA for menopausal hot flashes
How stereo-correct data can de-risk AI-driven drug discovery
eConsent as the digital foundation for modern clinical trials 
Female Patient Being Reassured By Doctor In Hospital Room
Q&A: Thermo Fisher’s Luke Wilson on hitting 100% dose delivery with patient-centric supply
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE